Media release

Küsnacht, April 8, 2020

BB Pureos Bioventures expands its team of Partners and Entrepreneurs with the appointment of Dr. Anja Harmeier

Pureos Bioventures, a venture capital fund of Bellevue Asset Management, is pleased to announce the recent appointment of Anja Harmeier, PhD, MBA, as a Partner. Anja brings more than 15 years of research and drug development experience to her role. Pureos Bioventures was able to attract significant new money from Swiss investors, but also from renowned international industrial and strategic investors from the USA and Asia. The fund invests in drug development with a focus on innovative biologics and next generation platforms. Initial investments were made in Alentis Therapeutics, NovaGo Therapeutics, AM Pharma and Eyevensys.

Prior to joining Pureos Bioventures, Anja started her own biotech company in the field of neurodegenerative disease. Subsequently, she moved to several positions with increasing responsibilities for preclinical research and early development at Roche in the fields of neuroscience, metabolic, hematological and rare diseases. Over the last four years Anja was an investment director at the Roche Venture fund sourcing, leading and managing investments in various areas, stages and locations like Black Diamond, Vivet, Entrada and NMD. Anja earned her PhD from the Free University of Berlin in Biochemistry studying the neurotoxicity of Amyloid beta and its prevention. In addition, Anja has an MBA with a focus on healthcare management from Instituto Empresa (IE) in Madrid.

"We are very pleased to welcome Anja at Pureos Bioventures. With her strong scientific background and expertise in developing novel treatments for severe diseases, Anja joins our venture fund, which is dedicated to investing in novel and innovative therapies," says Dr. Klaus Breiner, Managing Partner at Pureos Bioventures.

"Anja also brings additional expertise as a biotech entrepreneur. We think this expertise is important in order to best support and grow our young biotech companies in our portfolio," mentions Dr. Dominik Escher, Managing Partner at Pureos Bioventures.

"Furthermore, Anja has a strong corporate pharma venture expertise and a strong pharma network, which will be beneficial for our portfolio companies," added Dr. Martin Münchbach, Managing Partner at Pureos Bioventures.

As Partner of Pureos Bioventures, Anja is responsible for sourcing, investing and taking board leadership roles in novel investment opportunities and providing operational and strategic oversight of the Pureos Bioventures portfolio.

"Pureos Bioventures is one of few life-science venture firms in Switzerland primarily focused on investing in early-stage drug development companies and we share the same passion to transform breakthrough science into improved well-being of patients," noted Anja. "I am excited to be a part of Pureos Bioventures and look forward to building and leading innovative companies seeking to develop possible cures."

For more information:
Bellevue Asset Management AG, Seestrasse 16 / Postfach, 8700 Küsnacht/Zürich
Tanja Chicherio, Tel. 9,

About BB Pureos Bioventures
Pureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management, with offices in Zurich, London and New York. Active since 1993, Bellevue manages more than six billion dollars in the healthcare sector. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. With its dedicated and experienced team of venture capitalists and biotech entrepreneurs, Pureos strives to impact patients' lives by advancing innovative treatments for severe diseases. For further information, see

Disclaimer
The state of the origin of BB Pureos Bioventures L.P. (the "Fund") is Guernsey. For Switzerland: The Representative in Switzerland is ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zurich, whilst the Paying Agent is Bank am Bellevue, Seestrasse 16, 8700 Küsnacht, Switzerland. In Switzerland, the Fund documents may only be distributed to qualified investors within the meaning of Art. 10 Para. 3, 3bis and 3ter CISA. In respect of the units distributed in or from Switzerland, the place of jurisdiction is Guernsey. The basic documents of the Fund as well as the annual and the quarter-annual reports may be obtained free of charge at the registered office of the Swiss Representative.